Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
November 2024
Efficacy and safety of sodium-glucose co-transporter 2 inhibitors for the primary prevention of cardiovascular, renal events and safety outcomes in patients with systemic lupus erythematosus and comorbid type 2 diabetes: A population-based target trial emulation
Arthritis Rheumatol 2024. Epub ahead of print DOI: 10.1002/art.43037
Ma et al. assessed the efficacy and safety of sodium-glucose co-transporter 2 inhibitors (SGLT2i) compared with dipeptidyl peptidase 4 inhibitors (DPP4i) in preventing cardiovascular and renal events in patients with both SLE and type 2 diabetes (T2D). SGLT2i use significantly reduced risks for acute kidney injury, chronic kidney disease, end-stage renal disease, and heart failure, though it increased genital infection risk.
Keywords:
July 2024
Efficacy and safety of upadacitinib or elsubrutinib alone or in combination for systemic lupus erythematosus: A Phase 2 randomized controlled trial
Arthritis Rheumatol 2024 DOI: 10.1002/art.42926 Epub ahead of print
Daily oral upadacitinib 30 mg and ABBV-599 high dose (elsubrutinib 60 mg QD + upadacitinib 30 mg) were effective in multiple outcome measures including disease activity, flares, time to first flare, and joint counts.
Keywords:
October 2024
ANA-associated arthritis: clinical and biomarker characterization of a population for basket trials
Rheumatol 2024 2024;00:1–11 DOI 10.1093/rheumatology/keae269
Arnold et al. assessed musculoskeletal (MSK) inflammation in ANA-associated rheumatic diseases (RMDs) and redefined ANA-associated arthritis into two distinct multi-disease clusters based on disease activity, which may support a more targeted approach to treatment. The authors confirmed that MSK inflammation is a key feature across diagnoses and responded similarly to treatments.
Keywords:
February 2024
Development of the American College of Rheumatology's Patient-reported Outcome Quality Measures for Systemic Lupus Erythematosus
Arthritis Care Res (Hoboken). 2024 doi: 10.1002/acr.25301. Epub ahead of print.
Expert workgroup members and patient partners recommend that clinicians assess depression and physical function at least once yearly in all people with SLE. Additional patient reported outcome measures addressing cognition and fatigue can also be assessed.
December 2023
Association Between Severe Nonadherence to Hydroxychloroquine and Systemic Lupus Erythematosus Flares, Damage, and Mortality in 660 Patients From the SLICC Inception Cohort
Arthritis Rheumatol. 2023; 75(12):2195–2206 DOI: 10.1002/art.42645
n this study, severe nonadherence to hydroxychloroquine (HCQ) was independently associated with the risk of SLE flare in the following year, early damage and 5-year mortality.
Keywords:
Kidney Outcomes and Preservation of Kidney Function with Obinutuzumab in Patients with Lupus Nephritis: A Post Hoc Analysis of the NOBILITY Trial
Arthritis Rheumatol. 2023 DOI 10.1002/art.42734
This post hoc analysis of the Phase 2 NOBILITY trial determined that obinutuzumab plus standard of care improved the likelihood of long-term preservation of kidney function and improved kidney function with less glucocorticoid use in patients with lupus nephritis.
Keywords:
August 2023
Safety and Efficacy of Long-term Voclosporin Treatment for Lupus Nephritis in the Phase 3 AURORA 2 Clinical Trial
Arthritis Rheumatol. 2023;76(1):59–67 DOI: 10.1002/art.42657
AURORA 2 demonstrated the safety and tolerability of continued administration of voclosporin over 3 years of treatment in patients with LN.
Keywords:
July 2023
Update on the Efficacy and Safety Profile of Voclosporin: An Integrated Analysis of Clinical Trials in Lupus Nephritis
Arthritis Care Res (Hoboken). 2023 Jul;75(7):1399–1408 DOI: 10.1002/acr.25007
Pooled analysis of data from the AURA-LV phase 2 and AURORA 1 phase 3 trials of voclosporin in patients with active LN demonstrated that significantly more patients achieved a complete renal response at 1 year in the voclosporin than the control group (p<0.0001), with no observation of new safety signals.
May 2023
Development of American College of Rheumatology Quality Measures for Systemic Lupus Erythematosus: A Modified Delphi Process with RISE Registry Data Review
Arthritis Care Res (Hoboken). 2023 doi: 10.1002/acr.25143
The first ACR quality measures for SLE selected by Bartels, et al. use a rigorous Delphi process, and include recommendations on hydroxychloroquine, glucocorticoid reduction and kidney monitoring.
June 2023
Clinical and biomarker responses to BI 655064, an antagonistic anti-CD40 antibody, in patients with active lupus nephritis: a randomized, double-blind, placebo-controlled, phase II trial
Arthritis Rheumatol. 2023;75(11):1983–93 doi: 10.1002/art.42557.
This phase II study of BI 655064 in patients with active LN did not meet the primary endpoint of CRR at Week 52, however, post-hoc analyses suggest a potential benefit of BI 655064 180 mg in patients with active LN.